var data={"title":"Famciclovir: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Famciclovir: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6178?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=famciclovir-patient-drug-information\" class=\"drug drug_patient\">see &quot;Famciclovir: Patient drug information&quot;</a> and <a href=\"topic.htm?path=famciclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Famciclovir: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169842\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Famvir [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169843\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Famciclovir;</li>\n      <li>Ava-Famciclovir;</li>\n      <li>CO Famciclovir;</li>\n      <li>Famvir;</li>\n      <li>PMS-Famciclovir;</li>\n      <li>Sandoz-Famciclovir</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169877\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antiviral Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169845\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Genital herpes simplex virus (HSV) infection:</b> Oral: <b>Note:</b> Initiate therapy as soon as possible after diagnosis and within 72 hours of rash onset</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immunocompetent patients:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial episode (off-label use): 250 mg 3 times daily for 7 to 10 days. <b>Note:</b> Treatment can be extended if healing is incomplete after 10 days of therapy (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Recurrence:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Manufacturer&rsquo;s labeling: 1,000 mg twice daily for 1 day (<b>Note:</b> Initiate therapy as soon as possible and within 6 hours of symptoms/lesions onset)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Alternate dosing: 125 mg twice daily for 5 days or 500 mg as a single dose, followed by 250 mg twice daily for 2 days (CDC [Workowski 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Suppressive therapy: 250 mg twice daily. <b>Note:</b> Duration not established, but efficacy/safety have been demonstrated for 1 year (CDC [Workowski 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>HIV-infected patients:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer&rsquo;s labeling: Recurrent episodes: 500 mg twice daily for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Initial or recurrent episodes:</i> 500 mg twice daily for 5 to 10 days (HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Chronic suppressive therapy (off-label use):</i> 500 mg twice daily; suppressive therapy can be continued indefinitely regardless of CD4 count in patients with severe recurrences of genital herpes or in patients who want to minimize frequency of recurrences, or to reduce the risk of genital ulcer disease in patients with CD4 cell counts &lt;250 cells/mm<sup>3</sup> who are starting antiretroviral therapy. However, continuation of therapy should be reviewed annually, particularly if immune reconstitution has occurred (HHS [OI adult 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Herpes labialis/orolabial (cold sores):</b> Oral: <b>Note:</b> Initiate therapy as soon as possible after diagnosis and within 72 hours of rash onset</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immunocompetent patients:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Recurrent episodes: 1,500 mg as a single dose; initiate therapy at first sign or symptom such as tingling, burning, or itching (initiated within 1 hour in clinical studies)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>HIV patients:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer&rsquo;s labeling: Recurrent episodes: 500 mg twice daily for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: Treatment: 500 mg twice daily for 5 to 10 days (HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Herpes zoster (shingles):</b> Oral: <b>Note:</b> Initiate therapy as soon as possible after diagnosis and within 1 week of rash onset or any time before full crusting of lesions</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immunocompetent patients:</i> 500 mg every 8 hours for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>HIV-infected patients with acute localized dermatomal lesion (off-label use):</i> 500 mg 3 times daily for 7 to 10 days; consider longer duration if lesions heal slowly (HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>HIV-</i>\n      <i>infected patients with extensive cutaneous lesion or visceral involvement (off-label use)</i>: Initial therapy with acyclovir IV may be switched to famciclovir 500 mg 3 times daily to complete a 10 to 14 day course, when formation of new lesions has ceased and signs and symptoms of visceral VZV infection are improving (HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Varicella infection (chickenpox) in HIV-infected patients (uncomplicated cases) (off-label use):</b> Oral: 500 mg 3 times daily for 5 to 7 days (HHS [OI adult 2016])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45503347\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=famciclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Famciclovir: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Genital herpes simplex virus (HSV) in HIV-infected patients:</b> Adolescents (off-label population): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Initial or recurrent episodes:</i> 500 mg twice daily for 5 to 10 days (HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Chronic suppressive therapy (off-label use):</i> 500 mg twice daily; suppressive therapy can be continued indefinitely regardless of CD4 count in patients with severe recurrences of genital herpes or in patients who want to minimize frequency of recurrences, or to reduce the risk of genital ulcer disease in patients with CD4 cell counts &lt;250 cells/mm<sup>3</sup> who are starting antiretroviral therapy. However, continuation of therapy should be reviewed annually, particularly if immune reconstitution has occurred (HHS [OI adult 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Herpes labialis/orolabial (cold sores) in HIV-infected patients:</b> Adolescents (off-label population): Oral: Treatment: 500 mg twice daily for 5 to 10 days (HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Herpes zoster (shingles) in HIV-infected patients (off-label use) (HHS [OI adult 2016]):</b> Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Acute localized dermatomal lesion: </i>500 mg 3 times daily for 7 to 10 days; consider longer duration if lesions heal slowly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Extensive cutaneous lesion or visceral involvement (off-label use)</i>: Initial therapy with acyclovir IV may be switched to famciclovir 500 mg 3 times daily to complete a 10- to 14-day course, when formation of new lesions has ceased and signs and symptoms of visceral VZV infection are improving</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Varicella infection (chickenpox) in HIV-infected patients (uncomplicated cases) (off-label use):</b> Adolescents: Oral: 500 mg 3 times daily for 5 to 7 days (HHS [OI adult 2016])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169846\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169847\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Herpes zoster: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;60 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 40 to 59 mL/minute: Administer 500 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 20 to 39 mL/minute: Administer 500 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;20 mL/minute: Administer 250 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: Administer 250 mg after each dialysis session.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Recurrent genital herpes: Treatment:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Single-day regimen:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;60 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 40 to 59 mL/minute: Administer 500 mg every 12 hours for 1 day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 20 to 39 mL/minute: Administer 500 mg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;20 mL/minute: Administer 250 mg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis: Administer 250 mg as a single dose after a dialysis session.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternatively the following recommendations have been made (Famvir Canadian product labeling 2016):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;20 mL/minute/1.73 m<sup>2</sup>: Administer 125 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;20 mL/minute/1.73 m<sup>2</sup>: Administer 125 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis: Administer 125 mg after each dialysis session.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Recurrent genital herpes: Suppression:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;40 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 20 to 39 mL/minute: Administer 125 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;20 mL/minute: Administer 125 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: Administer 125 mg after each dialysis session.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Recurrent herpes labialis: Treatment (single-dose regimen):</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;60 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 40 to 59 mL/minute: Administer 750 mg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 20 to 39 mL/minute: Administer 500 mg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;20 mL/minute: Administer 250 mg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: Administer 250 mg as a single dose after a dialysis session.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Recurrent orolabial/genital (mucocutaneous) herpes in HIV-infected patients:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;40 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 20 to 39 mL/minute: Administer 500 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;20 mL/minute: Administer 250 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: Administer 250 mg after each dialysis session.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14274913\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Mild-to-moderate impairment: No dosage adjustment is necessary</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Severe impairment: No dosage adjustment provided in manufacturer&rsquo;s labeling; has not been studied. However, a 44% decrease in the C<sub>max</sub> of penciclovir (active metabolite) was noted in patients with mild-to-moderate impairment; impaired conversion of famciclovir to penciclovir may affect efficacy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169817\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Famvir: 125 mg [DSC], 250 mg [DSC], 500 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 125 mg, 250 mg, 500 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169803\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9537092\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: May be administered without regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169820\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of acute herpes zoster (shingles) in immunocompetent patients; treatment and suppression of recurrent episodes of genital herpes in immunocompetent patients; treatment of herpes labialis (cold sores) in immunocompetent patients; treatment of recurrent orolabial/genital (mucocutaneous) herpes simplex in HIV-infected adult patients</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45503346\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Genital herpes simplex virus (HSV) infection (initial episode); Herpes simplex virus (HSV) chronic suppressive therapy in HIV-infected patients (adolescents and adults); Herpes zoster (shingles) in HIV-infected patients (adolescents and adults); Varicella infection (chickenpox) in HIV-infected patients (adolescents and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6743664\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Famvir may be confused with Femara</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Famciclovir may be confused with acyclovir</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169810\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequencies vary with dose and duration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (9% to 23%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (11% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (&le;5%), migraine (&le;3%), paresthesia (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (2% to 4%), skin rash (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (2% to 8%), flatulence (&le;5%), vomiting (&le;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Dysmenorrhea (&le;8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Neutropenia (3%), leukopenia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (3%), increased serum AST (2%), increased serum bilirubin (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormal hepatic function tests, anaphylactic shock, anaphylaxis, anemia, angioedema (eyelid edema, facial edema, periorbital edema, pharyngeal edema), cholestatic jaundice, confusion, delirium, disorientation, dizziness, drowsiness, erythema multiforme, hallucination, hypersensitivity angiitis, palpitations, seizure, Stevens-Johnson syndrome, thrombocytopenia, toxic epidermal necrolysis, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169823\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to famciclovir, penciclovir, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169807\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required. Acute renal failure has been reported with use of inappropriate high doses in patients with underlying renal disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Lactose: Tablets contain lactose; do not use with galactose intolerance, severe lactase deficiency, or glucose-galactose malabsorption syndromes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Has not been established for use in initial episodes of genital herpes, recurrent episodes of genital herpes in Black and African-American patients, patients with ophthalmic or disseminated zoster, immunocompromised patients (except HIV-infected patients with orolabial or genital herpes).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299311\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6220317\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8435&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Talimogene Laherparepvec: Antiherpetic Antivirals may diminish the therapeutic effect of Talimogene Laherparepvec. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Varicella Virus Vaccine: Famciclovir may diminish the therapeutic effect of Varicella Virus Vaccine.  Management: When possible, avoid use of famciclovir within the 24 hours prior to administration of the varicella vaccine, and avoid use of famciclovir for 14 days after vaccination.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zoster Vaccine (Live/Attenuated): Famciclovir may diminish the therapeutic effect of Zoster Vaccine (Live/Attenuated).  Management: When possible, discontinue antiviral agents with anti-zoster activity (i.e., acyclovir, valacyclovir, famciclovir) for at least 24 hours prior to and 14 days after receiving a live attenuated zoster vaccine.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169839\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Rate of absorption and/or conversion to penciclovir and peak concentration are reduced with food, but bioavailability is not affected. Management: Administer without regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169813\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169827\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Based on available data, use during pregnancy appears to be well tolerated (CDC [Workowski 2015]; HHS [opportunistic; adult] 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Health care providers are encouraged to enroll women exposed to famciclovir during pregnancy in the Famvir Pregnancy reporting system (888-669-6682).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169828\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if famciclovir is excreted in breast milk. Breast-feeding is not recommended by the manufacturer unless the potential benefits outweigh any possible risk. If herpes lesions are on breast, breast-feeding should be avoided in order to avoid transmission to infant (AAP 2012).  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169815\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Periodic CBC during long-term therapy; renal function</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169806\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Famciclovir undergoes rapid biotransformation to the active compound, penciclovir (prodrug), which is phosphorylated by viral thymidine kinase in HSV-1, HSV-2, and VZV-infected cells to a monophosphate form; this is then converted to penciclovir triphosphate and competes with deoxyguanosine triphosphate to inhibit HSV-2 polymerase, therefore, herpes viral DNA synthesis/replication is selectively inhibited.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169822\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Food decreases maximum peak penciclovir concentration and delays time to penciclovir peak; AUC remains the same </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: Healthy adults: Penciclovir: 1.08 &plusmn; 0.17 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Penciclovir: &lt;20%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Famciclovir is rapidly deacetylated and oxidized to penciclovir (active prodrug); <i>in vitro</i> data demonstrate that metabolism does not occur via CYP isoenzymes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Penciclovir: 77% &plusmn; 8%  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Penciclovir: 2 to 4 hours; Prolonged in renal impairment:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl 40 to 59 mL/minute: ~3.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl 20 to 39 mL/minute: ~6.2 hours, </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl &lt;20 mL/minute: ~13.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intracellular penciclovir triphosphate: HSV 1: 10 hours; HSV 2: 20 hours; VZV: 7 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Penciclovir: ~1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (73% primarily as penciclovir); feces (27%) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169826\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Famciclovir Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg (30): $174.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (30): $189.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (30): $380.80</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038615\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Bencavir (LU);</li>\n      <li>Ezovir (AU);</li>\n      <li>Famcicool (KR);</li>\n      <li>Famcino (VN);</li>\n      <li>Famcir (KR);</li>\n      <li>Famcler (KR);</li>\n      <li>Famcro (KR);</li>\n      <li>Famicle (KR);</li>\n      <li>Famtrex (IN);</li>\n      <li>Famvir (AE, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BS, BZ, CH, CI, CY, CZ, DE, DK, EE, EG, ES, ET, FI, GB, GH, GM, GN, GR, GY, HK, HN, HR, HU, ID, IE, IL, IS, IT, JM, JO, JP, KE, KR, KW, LB, LR, LU, MA, ML, MR, MT, MU, MW, NE, NG, NL, NO, NZ, PK, PL, PT, QA, RU, SA, SC, SD, SE, SK, SL, SN, SR, TH, TN, TR, TT, TW, TZ, UA, UG, ZA, ZM, ZW);</li>\n      <li>Fanle (CN);</li>\n      <li>Favic (AU);</li>\n      <li>Fenalabial (IE);</li>\n      <li>Herfam (KR);</li>\n      <li>Oravir (FR);</li>\n      <li>Vectavir (LU);</li>\n      <li>Zosfam (KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alrabiah FA and Sacks SL, &ldquo;New Antiherpesvirus Agents. Their Targets and Therapeutic Potential,&rdquo; <i>Drugs</i>, 1996, 52(1):17-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/8799682/pubmed\" target=\"_blank\" id=\"8799682\">8799682</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP) Section on Breastfeeding. Breastfeeding and the use of human milk.<i> Pediatrics</i>. 2012;129(3):e827-841.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/22371471 /pubmed\" target=\"_blank\" id=\"22371471 \">22371471 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boike SC, Pue MA, and Freed MI, &ldquo;Pharmacokinetics of Famciclovir in Subjects With Varying Degrees of Renal Impairment,&rdquo; <i>Clin Pharmacol Ther</i>, 1994, 55(4):418-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/8162668/pubmed\" target=\"_blank\" id=\"8162668\">8162668</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boyd MR, Safrin S, and Kern ER, &ldquo;Penciclovir: A Review of Its Spectrum of Activity, Selectivity, and Cross Resistance Pattern,&rdquo; <i>Antivir Chem Chemother</i>, 1993, 4:3-11.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Daniels S and Schentag JJ, &ldquo;Drug Interaction Studies and Safety of Famciclovir in Healthy Volunteers: A Review,&rdquo; <i>Antivir Chem Chemother</i>, 1993, 4:57-64.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    De Clercq E, &ldquo;Antivirals for the Treatment of Herpesvirus Infections,&rdquo; <i>J Antimicrob Chemother</i>, 1993, 32(Suppl A):121-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/8407694/pubmed\" target=\"_blank\" id=\"8407694\">8407694</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. November 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Famvir (famciclovir) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; April 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Famvir (famciclovir) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Famvir (famciclovir) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gill KS and Wood MJ, &ldquo;The Clinical Pharmacokinetics of Famciclovir,&rdquo; <i>Clin Pharmacokinet</i>, 1996, 31(1):1-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/8827396/pubmed\" target=\"_blank\" id=\"8827396\">8827396</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goffin E, Horsmans Y, Pirson Y, et al, &ldquo;Acute Necrotico-Hemorrhagic Pancreatitis After Famciclovir Prescription,&rdquo; <i>Transplantation</i>, 1995, 59(8):1218-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/7537399/pubmed\" target=\"_blank\" id=\"7537399\">7537399</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed November 11, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hodge RA, &ldquo;Famciclovir and Penciclovir: The Mode of Action of Famciclovir Including Its Conversion to Penciclovir,&rdquo; <i>Antivir Chem Chemother</i>, 1993, 4:67-84.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Luber AD and Flaherty JF Jr, &ldquo;Famciclovir for Treatment of Herpesvirus Infections,&rdquo; <i>Ann Pharmacother</i>, 1996, 30(9):978-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/8876860/pubmed\" target=\"_blank\" id=\"8876860\">8876860</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pasternak B and Hviid A, &quot;Use of Acyclovir, Valacyclovir, and Famciclovir in the First Trimester of Pregnancy and the Risk of Birth Defects,&quot; <i>JAMA</i>, 2010, 304(8):859-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/20736469/pubmed\" target=\"_blank\" id=\"20736469\">20736469</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perry CM and Wagstaff AJ, &ldquo;Famciclovir. A Review of Its Pharmacological Properties and Therapeutic Efficacy in Herpesvirus Infections,&rdquo; <i>Drugs</i>, 1995, 50(2):396-415.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/8521764/pubmed\" target=\"_blank\" id=\"8521764\">8521764</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pue MA and Benet LZ, &ldquo;Pharmacokinetics of Famciclovir in Man,&rdquo; <i>Antivir Chem Chemother</i>, 1993, 4(Suppl 1):47-55.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sacks SL, &ldquo;Genital Herpes Simplex Virus and Its Treatment Focus on Famciclovir,&rdquo; <i>Semin Dermatol</i>, 1996, 15(2 Suppl 1):32-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/8840414/pubmed\" target=\"_blank\" id=\"8840414\">8840414</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spruance SL, Bodsworth N, Resnick H, et al, &ldquo;Single-Dose, Patient-Initiated Famciclovir: A Randomized, Double-Blind, Placebo-Controlled Trial for Episodic Treatment of Herpes Labialis,&rdquo; <i>J Am Acad Dermatol</i>, 2006, 55(1):47-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/16781291/pubmed\" target=\"_blank\" id=\"16781291\">16781291</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tyring SK, Barbarash RA, Nahlik JE, et al, &ldquo;Famciclovir for the Treatment of Acute Herpes Zoster: Effects on Acute Disease and Postherpetic Neuralgia,&rdquo; <i>Ann Intern Med</i>, 1995, 123(2):89-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/7778840/pubmed\" target=\"_blank\" id=\"7778840\">7778840</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tyring SK, &ldquo;Efficacy of Famciclovir in the Treatment of Herpes Zoster,&rdquo; <i>Semin Dermatol</i>, 1996, 15(2 Suppl 1):27-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/8840413/pubmed\" target=\"_blank\" id=\"8840413\">8840413</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015 [published correction appears in MMWR Recomm Rep. 2015;64(33):924]. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/26042815 /pubmed\" target=\"_blank\" id=\"26042815 \">26042815 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8435 Version 144.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F169842\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F169843\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F169877\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F169845\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F45503347\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F169846\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F169847\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F14274913\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F169817\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F169803\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F9537092\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F169820\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F45503346\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F6743664\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F169810\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F169823\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F169807\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299311\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6220317\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F169839\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F169813\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F169827\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F169828\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F169815\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F169806\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F169822\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F169826\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038615\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8435|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=famciclovir-patient-drug-information\" class=\"drug drug_patient\">Famciclovir: Patient drug information</a></li><li><a href=\"topic.htm?path=famciclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">Famciclovir: Pediatric drug information</a></li></ul></div></div>","javascript":null}